^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K d/? and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Published date:
11/04/2020
Excerpt:
High risk patients included 15% del 17p, 10% del 11q, 5% ZAP and 5% TP53 mutations….In all 21 evaluable pts with a median follow-up of 4.9 months, 7 patients showed partial response (33%) while the remaining 14 patients showed stable disease (67%)….Tenalisib showed promising single agent anti-tumor activity in patients with CLL with a favourable safety profile.